CMTM6 and glioma: Studies have shown that CMTM6 may serve as an unfavorable prognostic factor in glioma and a favorable prognostic factor in hepatocellular carcinoma [3, 5], and the relationship between the expression of PD-L1 and the prognosis of CRC is still controversial [20, 41].